General Information of Drug (ID: DMNG59Y)

Drug Name
4D-310 Drug Info
Indication
Disease Entry ICD 11 Status REF
Fabry disease 5C56.01 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMNG59Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Alpha-galactosidase A (GLA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pegunigalsidase alfa DMOUW65 Fabry disease 5C56.01 Approved [3]
Migalastat DMFIQ2H Fabry disease 5C56.01 Approved [4]
AVR-RD-01 DMC1XHK Fabry disease 5C56.01 Phase 1/2 [5]
ST-920 DMOJIPG Fabry disease 5C56.01 Phase 1/2 [6]
isaralgagene civaparvovec DM5SSPZ Fabry disease 5C56.01 Phase 1/2 [7]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [8]
Fucose DMAHMSV N. A. N. A. Investigative [8]
2,5-dideoxy-2,5-imino-D-altritol DMI1O54 Discovery agent N.A. Investigative [9]
Beta-1-C-Butyl-1-deoxygalactonojirimycin DMMKDEZ Discovery agent N.A. Investigative [9]
Beta-1-C-butenyl-1-deoxygalactonojirimycin DM6GTBC Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Alpha-galactosidase A (GLA) TTIS03D AGAL_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT04519749) An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of 4D Molecular Therapeutics
3 Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
4 AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
5 Clinical pipeline report, company report or official report of Avrobio.
6 AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev. 2020 Jul 9;18:607-619.
7 ClinicalTrials.gov (NCT04046224) A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR). U.S.National Institutes of Health.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4.